Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.80 |
| ▸ | MAPT | P10636 | 2/20 | 0.77 |
| ▸ | POLB | P06746 | 3/20 | 0.71 |
| ▸ | PKM | P14618 | 1/20 | 0.70 |
| ▸ | MEN1 | O00255 | 3/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.66 |
| ▸ | GAA | P10253 | 3/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4554939 | 1.00 | USP2 (0.80) | USP2MAPTPOLBPKMMEN1 | |
| SCHEMBL3236916 | 0.98 | MAPT (0.80) | USP2MAPTPOLBPKMMEN1 | |
| SCHEMBL423283 | 0.94 | MAPT (0.74) | USP2MAPTPOLBPKMMEN1 | |
| SCHEMBL208150 | 0.90 | POLB (0.73) | USP2MAPTPOLBPKMMEN1 | |
| SCHEMBL1711115 | 0.90 | PKM (0.85) | USP2MAPTPOLBPKMMEN1 | |
| SCHEMBL16964845 | 0.82 | PKM (0.68) | USP2MAPTPOLBPKMMEN1 | |
| SCHEMBL12793000 | 0.82 | ALDH1A1 (0.73) | USP2MAPTPOLBMEN1KMT2A | |
| SCHEMBL20387932 | 0.82 | ALDH1A1 (0.68) | USP2MAPTPOLBMEN1KMT2A | |
| Tert-Butyl Formate SCHEMBL28108074 | 0.81 | MAPT (0.58) | USP2MAPTPOLBPKMMEN1 | |
| SCHEMBL1797016 | 0.81 | MAPT (0.69) | MAPTPOLBPKMMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106061956-B | Heterocyclic sulfones as ROR gamma modulators | 百时美施贵宝公司 | 2021-03-12 | — | — | CN | disclosed |
| CN-105764900-B | CRTH2 agonist compounds and application thereof | 广东东阳光药业有限公司 | 2018-04-03 | — | — | CN | disclosed |
| CN-106061956-A | Heterocyclic sulfone as ror-gamma modulators | 百时美施贵宝公司 | 2016-10-26 | — | — | CN | disclosed |
| WO-2016128529-A1 | 1-(HET)ARYLSULFONYL-(PYRROLIDINE OR PIPERIDINE)-2-CARBOXAMIDE DERIVATIVES AND THEIR USE AS TRPA1 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2016-08-18 | — | — | WO | disclosed |
| US-6605618-B2 | Antidiabetic agents; hypoglycemic agents; anticholesterol agents; side effect reduction | WYETH | 2003-08-12 | — | — | US | disclosed |
| US-20030018045-A1 | Heterocyclic beta-3 adrenergic receptor agonists | WYETH (US) | 2003-01-23 | — | — | US | disclosed |
| US-6506901-B2 | 1-(9H-Carbazol-4-yloxy)-3-((1-(7-trifluoromethyl-quinolin-4-yl) -piperidin-4-lmethyl)-amino)-propan-2-ol, for example; treating diabetes, urinary continence, atherosclerosis, gastrointestinal disorders, glaucoma | WYETH | 2003-01-14 | — | — | US | disclosed |
| US-6451814-B1 | SUBSTITUTED 4-((4-AMINO-5-HYDROXYPHENYL)-OXY-)PIPERIDINE ANALOGS; METABOLIC DISORDERS; ANTIDIABETIC AGENTS; ATHERO-SCLEROSIS, GASTROINTESTINAL DISORDERS, GLAUCOMA, NEUROGENETIC INFLAMMATION, OCULAR HYPERTENSION AND FREQUENT URINATION | WYETH | 2002-09-17 | — | — | US | disclosed |
| US-20020037907-A1 | Substituted 2- (S) -hydroxy-3- (piperidin-4-yl-methylamino) -propyl ethers and substituted 2-aryl-2- (R) - hydroxy-1- (piperidin-4-yl-methyl) -ethylamine beta-3 adrenergic receptor agonists | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-03-28 | — | — | US | disclosed |
| US-20020028832-A1 | Heterocyclic beta-3 adrenergic receptor agonists | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-03-07 | — | — | US | disclosed |
| WO-2002006255-A2 | HYDROXY-(PIPERIDIN-4-YL-METHYLAMINO)-ALKYL BETA-3 ADRENERGIC RECEPTOR ANTAGONISTS | WYETH (US) | 2002-01-24 | — | — | WO | disclosed |
| WO-2002006229-A2 | HETEROCYCLIC BETA-3 ADRENERGIC RECEPTOR AGONISTS | WYETH (US) | 2002-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018045-A1 | Heterocyclic beta-3 adrenergic receptor agonists | ADRB2, ADRB1, ADRB3 | USP2 1752/4885MAPT 1539/4885POLB 2061/4885 |
| US-20020037907-A1 | Substituted 2- (S) -hydroxy-3- (piperidin-4-yl-methylamino) -propyl ethers and substituted 2-aryl-2- (R) - hydroxy-1- (piperidin-4-yl-methyl) -ethylamine beta-3 adrenergic receptor agonists | GPR119, ADRB1, ADRB2 | USP2 2605/4885MAPT 1657/4885POLB 2078/4885 |
| US-20020028832-A1 | Heterocyclic beta-3 adrenergic receptor agonists | ADRB1, ADRB3, ADRB2 | USP2 2158/4885MAPT 1106/4885POLB 2195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.